hAESCs will be administration through the Ommaya reservoir implanted into the lateral ventricle of subjects with idiopathic PD.~This dose escalation will be followed by an exploratory expansion phase in 3 cohorts.~Dose A (5×10^7 cells/dose)~Dose B (1.0×10^8 cells/dose)~Dose C (1.5×10^8 cells/dose).
This is a single-center, single-arm, dose escalation study, to explore the safety, tolerability and efficacy of human amniotic epithelial stem cells (hAESCs) for idiopathic Parkinson's disease (PD).